JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB221310

Recombinant mouse PD-L1 protein (Fc Chimera Active)

Be the first to review this product! Submit a review

|

(1 Publication)

Recombinant mouse PD-L1 protein (Fc Chimera Active) is a Mouse Fragment protein, in the 19 to 238 aa range, expressed in HEK 293 cells, with >95%, < 1 EU/µg endotoxin level, suitable for SDS-PAGE, ELISA, FuncS.

View Alternative Names

CD274, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1, Cd274, Programmed cell death 1 ligand 1, PD-L1, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1

3 Images
ELISA - Recombinant mouse PD-L1 protein (Fc Chimera Active) (AB221310)
  • ELISA

Supplier Data

ELISA - Recombinant mouse PD-L1 protein (Fc Chimera Active) (AB221310)

Immobilized ab221310 at 5 μg/mL (100 μL/well) can bind Recombinant mouse PD1 protein (Active) (Biotin) (ab246151) with a linear range of 0.313-5 μg/mL.

ELISA - Recombinant mouse PD-L1 protein (Fc Chimera Active) (AB221310)
  • ELISA

Supplier Data

ELISA - Recombinant mouse PD-L1 protein (Fc Chimera Active) (AB221310)

Immobilized Recombinant Mouse CD80 protein (Fc Chimera) (ab207101) at 5 μg/mL (100 μL/well) can bind ab221310 with a linear range of 0.16-2.5 μg/mL.

SDS-PAGE - Recombinant mouse PD-L1 protein (Fc Chimera Active) (AB221310)
  • SDS-PAGE

Supplier Data

SDS-PAGE - Recombinant mouse PD-L1 protein (Fc Chimera Active) (AB221310)

SDS-PAGE analysis of reduced ab221310 stained overnight with Coomassie Blue.

The protein migrates as 65-85 kDa on a SDS-PAGE gel under reducing conditions due to glycosylation.

Key facts

Purity

>95% SDS-PAGE

Endotoxin level

< 1 EU/µg

Expression system

HEK 293 cells

Tags

Fc tag C-Terminus

Applications

FuncS, SDS-PAGE, ELISA

applications

Biologically active

Yes

Biological activity

Measured by its binding ability in a functional ELISA. Immobilized ab221310 at 5 μg/mL (100 μL/well) can bind Recombinant mouse PD1 protein (Active) (Biotin) (ab246151) with a linear range of 0.313-5 μg/mL.

Measured by its binding ability in a functional ELISA. Immobilized Recombinant Mouse CD80 protein (Fc Chimera) (ab207101) at 5 μg/mL (100 μL/well) can bind ab221310 with a linear range of 0.16-2.5 μg/mL.

Accession

Q9EP73

Animal free

No

Carrier free

No

Species

Mouse

Reconstitution

Reconstitute at 400 µg/mL in water

Storage buffer

pH: 7.4 Constituents: PBS, 5% Trehalose

storage-buffer

style
left-column

Complementary Products

Primary Antibodies

AB205921

Anti-PD-L1 antibody [28-8]

BOND RX™ Validated|20ul selling size|Recombinant|KO Validated|Advanced Validation|RabMAb

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-PD-L1 antibody [28-8] (AB205921)

  • 4
  • 15
Proteins & Peptides

AB280753

Recombinant Human PD1 protein

Mass Spectrometry - Recombinant Human PD1 protein (AB280753)

  • 0
  • 0
Secondary Antibodies

AB150077

Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488)

Immunocytochemistry/ Immunofluorescence - Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (AB150077)

  • 5
  • 20
Primary Antibodies

AB52587

Anti-PD1 antibody [NAT105]

BOND RX™ Validated|Recombinant

Immunohistochemistry (Frozen sections) - Anti-PD1 antibody [NAT105] (AB52587)

  • 5
  • 9
style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "SDS-PAGE": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "FuncS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"" } } }
style
left-column

Product details

This product is stable after storage at:

  • -20°C to -70°C for 12 months in lyophilized state;
  • -70°C for 3 months under sterile conditions after reconstitution.
style
left-column

Sequence info

[{"sequence":"FTITAPKDLYVVEYGSNVTMECRFPVERELDLLALVVYWEKEDEQVIQFVAGEEDLKPQHSNFRGRASLPKDQLLKGNAALQITDVKLQDAGVYCCIISYGGADYKRITLKVNAPYRKINQRISVDPATSEHELICQAEGYPEAEVIWTNSDHQPVSGKRSVTTSRTEGMLLNVTSSLRVNATANDVFYCTFWRSQPGQNHTAELIIPELPATHPPQNRT","proteinLength":"Fragment","predictedMolecularWeight":"51.8 kDa","actualMolecularWeight":null,"aminoAcidEnd":238,"aminoAcidStart":19,"nature":"Recombinant","expressionSystem":"HEK 293 cells","accessionNumber":"Q9EP73","tags":[{"tag":"Fc","terminus":"C-Terminus"}]}]
style
left-column

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle
True
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

PD-L1 also known as Programmed Death-Ligand 1 or CD274 is a protein involved in immune modulation. Mechanically PD-L1 interacts with its receptors particularly PD-1 to regulate cellular immune responses. This transmembrane protein has a calculated molecular weight of approximately 33 kDa. PD-L1 is expressed on various cell types including tumor cells and immune cells such as dendritic cells macrophages and B cells. Its expression is often upregulated in response to inflammatory cytokines.
Biological function summary

PD-L1 plays a central role in immune evasion mechanisms utilized by tumors. It is not part of a larger protein complex but directly interacts with PD-1 and CD80. When PD-L1 binds to PD-1 it sends inhibitory signals leading to decreased T cell activation and proliferation allowing cancer cells to avoid immune destruction. PD-L1 expression provides a mechanism for tumors to suppress immune surveillance facilitating tumor progression.

Pathways

PD-L1 is integral to the immune checkpoint pathway which is an important regulator of immune response. The interaction between PD-L1 and PD-1 provides a mechanism for immune tolerance which is part of the broader adaptive immune system pathway. PD-L1 is related to other immune checkpoint proteins such as CTLA-4 in its function to limit autoreactivity and promote immune homeostasis.

PD-L1 is most associated with cancer particularly in tumors such as melanoma and non-small cell lung cancer. PD-L1 expression on tumor cells often correlates with poor prognosis. PD-L1 directly interacts with PD-1 in these cancers a target for immunotherapies such as checkpoint inhibitors which aim to block this interaction and restore immune activity against tumors. PD-L1 involvement extends to autoimmune disorders where altered expression can impact tolerance and lead to immune-related tissue damage.
style
left-column

Specifications

Form

Lyophilized

style
left-column

General info

Function

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).

Sequence similarities

Belongs to the immunoglobulin superfamily. BTN/MOG family.

Post-translational modifications

Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation. Ubiquitinated by MARCHF8; leading to degradation. Deubiquitinated by USP22; leading to stabilization.

Subcellular localisation

Early endosome membrane

style
left-column

Product protocols

style
left-column

Target data

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed : 11238124). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed : 11238124). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed : 11015443, PubMed : 12719480).. The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed : 12218188, PubMed : 27281199). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (PubMed : 12218188). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (PubMed : 12218188).
See full target information Cd274
style
left-column

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Neuron 111:2709-2726.e9 PubMed37348508

2023

PD-L1/PD-1 checkpoint pathway regulates hippocampal neuronal excitability and learning and memory behavior.

Applications

Unspecified application

Species

Unspecified reactive species

Junli Zhao,Sangsu Bang,Kenta Furutani,Aidan McGinnis,Changyu Jiang,Alexus Roberts,Christopher R Donnelly,Qianru He,Michael L James,Miles Berger,Mei-Chuan Ko,Haichen Wang,Richard D Palmiter,Ru-Rong Ji
View all publications
style
left-column
style
left-column
style
right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com